IL2 and neoplasm: The use of antibody–cytokine fusion proteins, called immunocytokines, is especially attractive (17), as immunocytokines can deliver cytokines such as interleukin 2 (IL-2) to the tumor activating the patients’ own cytotoxic T cells while reducing Treg numbers within the tumor and adjacent lymph nodes (18).